Published on : May 23, 2016
ALBANY, New York, May 23, 2016: A new market research report, titled “Frontier Pharma: Schizophrenia and Associated Indications - Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms,” featured on ResearchMoz.us, analyzes the market by stating its current value, size, performance, and statistics. The report is an in-depth study of the key dynamics of the global schizophrenia and associated indications market.
The report discusses the growing opportunities for biological products and diversification of molecular targets. Innovative first-in-class product developments remain an attraction for the key operators in the global schizophrenia and associated indications market. Tables, charts, graphs, and statistics have been to illustrate qualitative research findings.
The report includes information such as common targets and mechanisms of action for pipeline therapies for schizophrenia. The study helps readers to understand the current commercial and clinical landscape by considering diagnosis, prognosis, disease pathogenesis, and treatment options available at every stage of diagnosis. It also includes a clinical comparison of marketed therapies.
Click here to get more info with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=716912
The clinical and commercial landscape has been discussed, including disease overview, epidemiology, disease etiology, disease pathophysiology, susceptibility genes, neurotransmission alterations, phosphatidylinositol signaling, and disease symptoms. The report includes a thorough evaluation of pipeline programs targeting D-amino acid oxidase, gamma-aminobutyric acid receptor, subunit alpha, glutamate carboxypeptidase, phosphodiesterase, G protein-coupled receptor, and potassium voltage-gated channel subfamily C.
Schizophrenia is a severe mental disorder affecting the social behavior of a patient. A schizophrenia patient fails to recognize what is real and what is imaginary. Patients are unresponsive and withdrawn, finding it difficult to express normal emotions in social situations. Symptoms include false beliefs, confused thinking, hearing voices, and reduced social engagement. Patients also suffer from anxiety disorders or major depressive illness.
The treatment of schizophrenia is multi-factorial and includes the use of medical, psychosocial, and psychological inputs. Job training, counselling, and social rehabilitation may be provided to the patient as part of the treatment process. Antipsychotic medication, both typical and atypical, is used and comprises the main pharmacological agent administered to a patient. Clozapine, which is an atypical antipsychotic, is often given to patients in case there are no signs of improvement with other antipsychotics.
Schizophrenia symptoms are broadly divided into positive, negative, and cognitive, of which there is effective treatment available for positive symptoms. The current treatments available are not as effective for cognitive dysfunction and negative symptoms. The unmet needs in the current schizophrenia and associated treatment market are highlighted in the report, thus allowing a better understanding of the gaps in the current market. The future of first-in-class targets is assessed and ranked according to the clinical potential. Schizophrenia is a poorly understood disorder with many unmet needs and a small pipeline for schizophrenia with few innovations. However, there is an extensive pipeline for associated indications. The report helps readers tap into commercial opportunities that have thus far remained unexplored.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org